Intuitive Surgical
The maker of the da Vinci surgical robot: a hospital buys the machine once, then buys Intuitive's instruments, which stop working after a set number of uses, for every operation.
Our viewNeutral Medium conviction
The scores
The profile · 1-4
Growth4/4 ↓
Revenue grew 20.5% in 2025 and 18.5% over the trailing year, organically and broadly - but all of it is volume, not price.
Business quality3/4 ↓
The system lock is structural, but the instrument lock behind three quarters of revenue is contested in court and rivals are cleared to rebuild instruments.
Financial position4/4 →
$8.63B of cash and investments, no borrowings of any kind, nothing to refinance, and a plan funded several times over by its own cash flow.
Execution record3/4 →
Beat every estimate for eight quarters, but US procedure growth came in below its own start-of-year expectation and that was not flagged in advance.
Per share capture4/4 ↑
Share count falling, repurchases of $1.44B against a $426.1M compensation charge, acquisitions in cash, no debt. The holder gets it all.
Potential3/4 →
A large upside on observable steps - robotic share rising, day-surgery centres, benign operations abroad - but the leases are the only thing actually committed.
Risk profile2/4 →
A certified class action over three quarters of revenue goes to trial inside the horizon, externally controlled, with the company unable to estimate the loss.
Valuation2/4 ↑
At $39.50 for each dollar of yearly operating profit, the price needs 13% to 15% procedure growth for years and stable revenue for each operation.
Evidence quality3/4 →
Central claims are filed facts with outside corroboration; the largest item, the price cut, is management's own 3% to 5% range.
The Verdict
We rate Intuitive Surgical neutral. It makes the da Vinci surgical robot, and hospitals buy its instruments for every operation, so most revenue repeats and keeps growing fast; the business is strong. From 2027 it will cut the price of those instruments by 3% to 5%, and American operations grew only 10% in the latest quarter. The price is full, not cheap: it counts on years of fast growth with steady revenue from each operation, leaving no room for the instrument cut. An excellent business, priced as though little changes.
The long caseSurgery keeps moving from open incisions and hand-held tools onto robots; Intuitive must grow operations fast enough to make up for cutting its instrument prices.
The evidence under this - 7 claims
C02facthigh confidence
Instruments and accessories of $1,734.9M plus service of $472.4M were $2,207.3M of Intuitive's $2,892.3M of Q2 2026 revenue, or 76.3%; systems were the remaining $685.0M.
C03facthigh confidence
Intuitive had approximately 11,106 da Vinci systems installed at 31 December 2025, and management said the combined da Vinci and Ion installed base passed roughly 13,000 systems during Q2 2026.
C04facthigh confidence
Approximately 3,153,000 da Vinci procedures were performed in 2025, up 18% on approximately 2,683,000 in 2024; Ion procedures were approximately 144,100, up 51%.
C25management claimhigh confidence
From the first half of 2027 Intuitive plans to increase the number of uses on a subset of EndoWrist instruments, lowering customer cost for each use, targeted at high-volume benign procedures; force feedback, stapling and energy products are excluded.
against this
- Management frames this as an investment in adoption - lower cost supports broader use, which drives utilisation and scale. That framing is unfalsifiable in advance and is the seller describing its own price cut.
- The exclusions are the growing, higher-priced lines: force feedback, stapling and energy. Excluding exactly the instruments whose revenue for each procedure is rising is consistent with defending a headline figure as well as with a targeted cost initiative.
- The 10-K discloses in the same period that the FDA has cleared third parties to remanufacture instruments for the Si, X and Xi generations - the same generations whose instrument lives are now being extended.
C26management claimhigh confidence
On its Q3 2026 call on 20 October 2026 Intuitive quantified the instrument pricing actions, the extended use programme and a policy-driven price cut in China from November 2026, at approximately 3% to 5% of da Vinci instrument and accessory revenue for each procedure on a mix-constant basis once fully implemented, against 7% for the 2020 programme; the offsets from force feedback, single-port and da Vinci 5 instruments are not in that figure.
against this
- The 3% to 5% bundles the extended use programme with China's policy cut, so the programme's own share is not stated, and it is struck holding mix constant while management says the offsets are positive and unquantified.
- The United States rollout needs a 510(k) clearance still in process; management expects to start later in the first quarter of 2027 and Europe in the second half of 2027, and said it does not expect the full impact before the end of 2027, which is the 'mostly inside 2027' branch of the pre-registered test.
- 2026-10-21editedQ3 2026 call: management quantified the pricing actions at about 3% to 5% of revenue for each procedure, including China, with the full effect by the end of 2027.
C42estimatehigh confidence
At an enterprise value of $136.19B against trailing operating profit of $3.45B, buyers pay $39.50 for each dollar of yearly operating profit - $43,195 of company value for each of the 3,153,000 da Vinci procedures performed in 2025, about 24 times the $1,830 of instrument revenue one procedure yields in a year.
derivedEnterprise value and market value from the pack; trailing operating profit from the four filed quarters to 30 June 2026; procedure count from the 2025 10-K; revenue for each procedure from the Q2 2026 call.
against this
- The denominator is one year's procedures on an installed base that grew 12%, so dividing by a growing number flatters nothing but also understates the multiple against the base that will exist in three years.
- Instrument revenue is not the only revenue each procedure generates - service and lease revenue also scale with the installed base - so 24 times understates what a procedure is worth to the company and overstates how demanding the price is on that one measure.
- Trailing operating profit is struck after a $36M one-off tariff refund and after research and development that management is deliberately growing faster than revenue.
C24management claimhigh confidence
On 20 October 2026 Intuitive narrowed its full-year 2026 da Vinci procedure growth outlook to 14% to 15%, closer to the midpoint, from 13.5% to 15.5%, after da Vinci procedures grew 14% and total procedures 15% in Q3 2026.
sourceQ2 2026 earnings call transcriptprimaryQ3 2026 earnings call transcriptprimaryForm 8-K and Exhibit 99.1 earnings release for the quarter…primary
against this
- The midpoint of 14.5% is unchanged; narrowing removes the tails and still considers ACA premium subsidy changes and China tender volumes and competitive intensity, among other factors.
- Worldwide growth of 14% is carried by outside-US growth of 20%; United States growth was 10%.
- 2026-10-21editedQ3 2026 results and call: outlook narrowed to 14% to 15% after da Vinci procedure growth of 14% in the quarter.
The company
In keyhole surgery the surgeon works through small cuts with long rigid tools that cannot bend at the tip, so stitching at awkward angles is hard. The da Vinci puts wristed instruments on robotic arms, driven from a console beside the patient.
It is replacing both that and open surgery: robotic operations rose from 1.8% to 15.1% of general surgery in Michigan hospitals between 2012 and 2018. About 3.15 million operations were done on da Vinci systems in 2025.
The evidence under this - 3 claims
C01facthigh confidence
Intuitive sells the da Vinci surgical system - robotic arms a surgeon drives from a console - together with the wristed instruments each operation consumes and a service contract on the machine.
C20facthigh confidence
Robotic surgery rose from 1.8% of general surgery procedures in 2012 to 15.1% in 2018 across 73 Michigan hospitals, a slope of 2.1 percentage points a year, while open surgery fell from 42.4% to 32.4%.
C04facthigh confidence
Approximately 3,153,000 da Vinci procedures were performed in 2025, up 18% on approximately 2,683,000 in 2024; Ion procedures were approximately 144,100, up 51%.
How it makes money
The machine is sold or leased once. Then every operation uses about $1,830 of Intuitive's instruments, each licensed for a set number of uses before it stops working, and the hospital pays for servicing. Instruments and service were 76.3% of revenue in the June 2026 quarter: money that arrives with each operation, not with each machine.
The evidence under this - 3 claims
C05management claimmedium confidence
da Vinci instrument and accessory revenue for each procedure was approximately $1,860 in Q3 2026, against approximately $1,800 a year earlier, driven by more single-port procedures and da Vinci 5 specific instruments and partly offset by procedure mix.
against this
- Management attributed the sequential decline from Q1 2026 to customer ordering patterns that were elevated in Q1, especially outside the United States - which is a claim that a fall was a timing effect and cannot be checked from outside.
- The figure is disclosed nowhere in the 10-Q or the 10-K. Dividing filed instrument revenue by the filed procedure count gives a different number because instrument revenue includes Ion consumables.
- 2026-10-21editedQ3 2026 call: revenue for each procedure was about $1,860 against about $1,800 a year earlier.
C02facthigh confidence
Instruments and accessories of $1,734.9M plus service of $472.4M were $2,207.3M of Intuitive's $2,892.3M of Q2 2026 revenue, or 76.3%; systems were the remaining $685.0M.
C01facthigh confidence
Intuitive sells the da Vinci surgical system - robotic arms a surgeon drives from a console - together with the wristed instruments each operation consumes and a service contract on the machine.
Where the money comes from, stream by stream
| Stream | Share of sales (FY2025) | How it earns it |
|---|---|---|
| Instruments and accessories | 59.8% | The wristed instruments, staplers and accessories each da Vinci or Ion operation uses up, priced per use and bought again for every case. |
| Systems | 24.6% | The robots themselves, sold outright or leased; about half are leased, and part of lease revenue rises with how much the machine is used. |
| Service | 15.6% | Yearly service contracts on every installed system, which grow with the installed base. |
Who runs it
Dave Rosa, an engineer with nearly 30 years at Intuitive, became chief executive in July 2025; Gary Guthart, who ran it before him, stays on as full-time chair. Jamie Samath has run finance since 2022. Insiders own well under 1% of the company. The yearly bonus rides on operating profit and on goals the company keeps private; most share awards pay on how many operations are done, none on what each operation earns.
The evidence under this - 3 claims
C68facthigh confidence
David J. Rosa, with Intuitive for nearly 30 years in engineering, clinical, commercial and product roles, became chief executive on July 1, 2025; Gary S. Guthart, chief executive until June 30, 2025, became full-time executive chair; Jamie E. Samath, at Intuitive since 2013, has been chief financial officer since January 2022.
C69facthigh confidence
At December 31, 2025 the 17 executive officers and directors as a group beneficially owned 2,260,608 shares, 0.6% of the 355,052,975 outstanding, including 555,917 shares under exercisable options; Gary Guthart's 1,512,213 was the largest insider holding and Dave Rosa's 439,066 the next; Vanguard at 9.5% and BlackRock at 8.6% were the only holders above 5%. There is one class of common stock.
C70facthigh confidence
Intuitive's 2025 annual bonus pool was funded half on adjusted operating income ($3.969B against a $3.368B target, paying the 125% maximum) and half on company performance goals it does not disclose (105.3%), for 115.2% overall; for 2026 the weights are 35% and 65%. Half of executives' equity is PSUs: two-thirds pay on growth in da Vinci and Ion procedure counts from 2024 to 2026 and to 2027, one-third on adjusted operating margin ranked against 20 device makers over 2025 to 2027, which replaced relative shareholder return; the 2026 PSUs are similar.
against this
- No metric pays on revenue per procedure or instrument pricing, so the extended use programme (C25), which lowers what a hospital pays per use, costs the plan's largest equity metric nothing and may help it.
- Most of the 2026 bonus rides on goals nobody outside can check.
Why it wins, and who could beat it
Why customers come back
Once a hospital owns a da Vinci and has trained its surgeons, it buys its instruments from Intuitive, whose system counts each one's uses. Leaving means writing off the machine and retraining the team.
Outsiders have tested that grip. A federal court ruled in 2024 that Intuitive held monopoly power over replacing its instruments, then withdrew the finding. For the hospital the price is small against what goes wrong in surgery: $1,830 an operation, against about $30,000 added by one surgical infection.
The evidence under this - 4 claims
C05management claimmedium confidence
da Vinci instrument and accessory revenue for each procedure was approximately $1,860 in Q3 2026, against approximately $1,800 a year earlier, driven by more single-port procedures and da Vinci 5 specific instruments and partly offset by procedure mix.
against this
- Management attributed the sequential decline from Q1 2026 to customer ordering patterns that were elevated in Q1, especially outside the United States - which is a claim that a fall was a timing effect and cannot be checked from outside.
- The figure is disclosed nowhere in the 10-Q or the 10-K. Dividing filed instrument revenue by the filed procedure count gives a different number because instrument revenue includes Ion consumables.
- 2026-10-21editedQ3 2026 call: revenue for each procedure was about $1,860 against about $1,800 a year earlier.
C07facthigh confidence
On 31 March 2024 a federal court ruled that the da Vinci robot and EndoWrist instruments occupy separate product markets for antitrust purposes, that an aftermarket exists for their repair and replacement, and that Intuitive holds monopoly power in it.
C08facthigh confidence
On 30 July 2024 the court vacated those market-definition findings on Intuitive's motion for reconsideration, and on 31 March 2025 it certified the plaintiff class and set trial for 14 September 2027. In October 2026, after mediation, Intuitive agreed in writing to settle the class action, without admitting liability, for a one-time $450M payment and mutually agreed injunctive relief, a charge it booked in the third quarter; the settlement still needs preliminary and final court approval and the injunctive terms were not stated in the release. On the call management said the agreement is with US customers in the class action and covers third-party instrument remanufacturers and third-party service providers, sets a framework for how the two work together, and that it does not expect the court's decision until 2027.
sourceForm 10-Q for the quarter ended June 30, 2026primaryForm 8-K and Exhibit 99.1 earnings release for the quarter…primaryQ3 2026 earnings call transcriptprimary
- 2026-10-20editedQ3 2026 results release: the hospital class action was settled for $450M plus injunctive relief, subject to court approval, so the September 2027 trial date no longer stands as the live path.
- 2026-10-21editedQ3 2026 call: scope of the settlement described by management; the injunctive terms are still not published.
C09facthigh confidence
The costliest inpatient harms, including surgical site infections, add approximately $30,000 to the cost of the hospital stay.
The threat
Rivals attack from three sides. Medtronic's Hugo robot was cleared for urology in December 2025, and Johnson & Johnson has filed its Ottava robot for upper-abdominal surgery. Restore Robotics is cleared to rebuild Intuitive's own instruments, going after the instruments without touching the robot. And obesity drugs are removing some patients altogether: weight-loss operations on da Vinci are falling.
The evidence under this - 6 claims
C12facthigh confidence
Medtronic received FDA clearance for the Hugo robotic-assisted surgery system in urologic procedures in December 2025, and on 3 June 2026 submitted 510(k) filings for general surgery including hernia repair and for gynecologic surgery.
C14factmedium confidence
Johnson & Johnson submitted the Ottava robotic surgical system to the FDA for De Novo classification on 7 January 2026, for multiple general surgery procedures in the upper abdomen.
C16factmedium confidence
Restore Robotics announced two further FDA clearances to remanufacture da Vinci Xi instruments on 31 March 2026, and states that Intuitive has granted approval under its contracts for it to remanufacture any EndoWrist covered by an FDA clearance.
against this
- The second half is the remanufacturer's characterisation of its own contract with Intuitive, not a filed document. Intuitive's 10-K says it generally does not approve customer use of unauthorised instruments, which is not the same statement and may not be inconsistent with it - an approved remanufacturer is by definition authorised.
- Restore Robotics is simultaneously suing Intuitive for antitrust; its complaint was dismissed in November 2025 and is on appeal. A litigant describing its own access is an interested witness.
C15facthigh confidence
Intuitive's 10-K states that the FDA has granted 510(k) clearance for the remanufacturing of certain of its instruments for use with da Vinci Si, X and Xi systems, and that such offerings have not had a material impact on its revenues to date.
C35facthigh confidence
The 2025 10-K states that the availability and effectiveness of weight loss drugs have reduced the number of bariatric procedures performed, including those performed using the da Vinci surgical system.
C34management claimhigh confidence
US da Vinci procedure growth was 10% in Q3 2026, against 12% in Q2 2026 and 14% in Q1 2026; management said 10% matched its July expectation and reflects 16% growth in the prior-year quarter, the hardest comparison of the year, and that it is monitoring lower ACA enrollment, Medicaid eligibility changes and potential changes to 340B. US bariatric cases declined at a high single-digit rate in Q2 2026 on rising use of obesity drugs.
against this
- Wells Fargo's analyst called 10% the lowest growth since the pandemic, although stable over two years combined; management gave no recovery figure.
- Management attributed the slowdown to the comparison and to coverage changes, two explanations with different implications, neither quantified. Medtronic's FY2026 10-K independently reports bariatric declines.
- US net da Vinci placements rose 41% and US system placements 27% to 335, which management cited as capacity for later procedure growth.
- 2026-10-21editedQ3 2026 call: US da Vinci procedure growth was 10%, below the 11% line of the pre-registered test.
The rivals: MDT, JNJ, SSII, and 2 more that are private, in-house or listed abroad.
Who else does this, rival by rival
| Ticker | Rival | How far along | Priced against it |
|---|---|---|---|
| MDT | Medtronic's Hugo robotic-assisted surgery systemPriced against it: Small part of it | On sale | Small part of it |
| JNJ | Johnson & Johnson's Ottava robotic surgical systemPriced against it: Different product | Announced | Different product |
| Private | Restore Robotics, remanufacturing Intuitive's own EndoWrist instrumentsPriced against it: Private | On sale | Private |
| Not listed | Obesity drugs, principally the GLP-1 classPriced against it: Not listed | On sale | Not listed |
| SSII | SS Innovations InternationalPriced against it: Same product | On sale | Same product |
How big it could get
How big this could get
America performed about 14.2 million inpatient operations in 2014. At the 15.1% robotic share last measured and $1,830 of instruments each, that is about $3.92B a year. Intuitive's American instrument sales already run near $4.72B, so the count misses a lot: operations outside hospital wards, and all the growth in robotic share since 2018, which nobody has measured since.
The evidence under this - 5 claims
C19facthigh confidence
In 2014, 10.1 million inpatient hospital stays in the United States involved operating room procedures, with a total of 14.2 million such procedures.
C20facthigh confidence
Robotic surgery rose from 1.8% of general surgery procedures in 2012 to 15.1% in 2018 across 73 Michigan hospitals, a slope of 2.1 percentage points a year, while open surgery fell from 42.4% to 32.4%.
C05management claimmedium confidence
da Vinci instrument and accessory revenue for each procedure was approximately $1,860 in Q3 2026, against approximately $1,800 a year earlier, driven by more single-port procedures and da Vinci 5 specific instruments and partly offset by procedure mix.
against this
- Management attributed the sequential decline from Q1 2026 to customer ordering patterns that were elevated in Q1, especially outside the United States - which is a claim that a fall was a timing effect and cannot be checked from outside.
- The figure is disclosed nowhere in the 10-Q or the 10-K. Dividing filed instrument revenue by the filed procedure count gives a different number because instrument revenue includes Ion consumables.
- 2026-10-21editedQ3 2026 call: revenue for each procedure was about $1,860 against about $1,800 a year earlier.
C21estimatemedium confidence
US inpatient operating-room procedures of 14.2 million a year, at the 15.1% robotic share last measured, at approximately $1,830 of instrument revenue each, comes to about $3.92B of annual instrument revenue - against US instrument and accessory revenue already running at about $4.72B.
derivedC19 multiplied by C20's endpoint share multiplied by C05's revenue for each procedure, against C22's US instrument revenue annualised from Q2 2026.
against this
- The three inputs are measured in different years - the base in 2014, the share in 2018, the price in 2026 - so the arithmetic is an order-of-magnitude bound rather than a market size. US inpatient procedure counts have almost certainly changed since 2014 and robotic share has almost certainly risen since 2018.
- The AHRQ base is inpatient only. A large and growing share of the procedures da Vinci performs are outpatient, including the ambulatory surgery centres Intuitive placed 27 systems into in Q2 2026, so the base understates the addressable count.
- The base also includes orthopaedic, cardiac and neurosurgical procedures da Vinci is not cleared for, so it overstates in the other direction. The two errors do not cancel in a knowable way.
C22facthigh confidence
US instrument and accessory revenue was $1,180.4M in Q2 2026, and the United States was 67% of total revenue in the quarter.
Where the growth is coming from, business by business
Where the growth is coming from
| Business | Share of revenue | Growth: last quarter | Last half-year | Last year | Share in 3 years at its half-year rate |
|---|---|---|---|---|---|
| Instruments and Accessories | 59% | +18.3% | +18.0% | +19.1% | 56% |
| Systems | 25% | +30.3% | +24.8% | +23.4% | 28% |
| Services | 16% | +21.8% | +21.3% | +20.9% | 16% |
| Whole company | 100% | +21.7% | +20.1% | +20.5% | 100% |
On the filed split through 2026-09-30, if each business keeps its last half-year's growth, the company grows about 20% next year and 20% in year 3, against 20.7% over the last twelve months. A scenario, not a forecast: no business holds its rate.
The results
The numbers
Is it growing?Steady
Sales grew 20% over the twelve months to Sep 2026, about the same pace as the 21% in the year to Dec 2025.
Is it profitable?Strong
Operating margin is 28%, up from 25% in the year to Dec 2023.
Does growth pay off?Flat
Running costs take 39¢ of each sales dollar, up from 37¢ in the year to Dec 2021.
Does it earn good returns?Decent
Each dollar put into the business earns 16% a year after tax, about where it was (15%) in the year to Dec 2021.
Is it making cash?Strong
It turned 31% of sales into free cash, $3.60B over the last twelve months.
How steady is it?Uneven
Yearly sales growth has ranged from +9.0% to +31% over the last 5 years.
Are shares being diluted?Stable
The share count fell 3.9% in 4.8 years, and pay in shares costs 7.3% of sales.
All the numbers
Filed figures from the company's 10-K and 10-Q, read 2026-10-21. Fiscal years end in December.
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | 12 mo to Sep 2026 | |
|---|---|---|---|---|---|---|
| Size and growth | ||||||
| Sales | $5.71B | $6.22B | $7.12B | $8.35B | $10.1B | $11.6B |
| Sales growth | +31% | +9.0% | +14% | +17% | +21% | +20% |
| Profit | ||||||
| Gross margin | 69% | 67% | 66% | 67% | 66% | 67% |
| Operating margin | 32% | 25% | 25% | 28% | 29% | 28% |
| Net margin | 30% | 21% | 25% | 28% | 28% | 26% |
| What growth costs, per sales dollar | ||||||
| Research and development | 12% | 14% | 14% | 14% | 13% | 13% |
| Selling, general and admin | 26% | 28% | 28% | 26% | 24% | 22% |
| Pay in shares | 8.0% | 8.3% | 8.4% | 8.2% | 8.0% | 7.3% |
| Capital spending | 5.9% | 8.6% | 15% | 13% | 5.4% | 4.2% |
| Cash | ||||||
| Cash from operations | $2.09B | $1.49B | $1.81B | $2.42B | $3.03B | $4.09B |
| Free cash flow | $1.75B | $958M | $750M | $1.30B | $2.49B | $3.60B |
| Balance sheet | ||||||
| Cash and short-term investments | $4.20B | $4.12B | $5.22B | $4.01B | $5.93B | $4.04B |
| Returns and shares | ||||||
| Return on capital | 15% | 12% | 13% | 14% | 15% | 16% |
| Shares (diluted) | 366M | 362M | 357M | 362M | 363M | 352M |
What growth costs
Growth has not made Intuitive more profitable lately. Selling and running the company take a smaller slice of each sale, and the big building programme is finished, but research takes a slightly bigger slice and each sale keeps a little less after making the product. The two roughly cancel out, so the margin is about where it was five years ago.
The evidence under this - 1 claim
C67facthigh confidence
Per sales dollar, selling, general and administrative spending fell from 25.7 cents in 2021 to 23.7 in 2025 and 22.6 over the four quarters to June 2026; R&D rose from 11.8 to 13.0 and 12.8; stock pay went from 8.0 to 8.0 and 7.6; capital spending from 5.9 to a peak of 14.9 in 2023 and back to 4.4. Gross margin went from 69.3% to 66.0% and 66.7%, operating margin from 31.9% to 29.3% and 31.3%.
sourceIntuitive Surgical XBRL company facts (SEC companyfacts), as…primaryForm 10-K for the fiscal year ended December 31, 2025primaryForm 10-Q for the quarter ended June 30, 2026primary
against this
- Measured from 2020 (24.1% operating margin) or 2023 (24.8%) instead of 2021 the same lines read as widening leverage, so the reading depends on the base year.
- Part of the gross margin slide is tariffs, about $63.0M of cost in 2025 (C33), which is not a cost of growth.
The last report (16 Jul)
Quarter ended June 2026, filed figures.
19%
Sales growth
against the same quarter a year earlier
4.4%
Growth from the quarter before
against -3.3% the quarter before that
34¢
Operating profit
per dollar of sales
The September quarter beat forecasts: revenue grew 22% to just over $3B and adjusted profit per share was $3.00 against $2.65 expected. Operations on da Vinci robots grew 14%, but only 10% in the United States, the slowest in years.
On the call, management put its instrument price cuts, including China's from November, at 3% to 5% of revenue for each operation once fully in place, with the full effect by the end of 2027. It also settled the hospital class action for $450M.
What it did to the thesisThe cut came out at the low end of what we feared, and worldwide growth covers it comfortably. But American growth fell below our line, so the test read against us. Neither half of the price moved enough to change the view.
The quarter in detail
Sales growth from the previous quarter, filed figures.
Earnings per share $2.80 against $2.48 expected; $2.29 as filed, the gap being what the company adds back.
The evidence under this - 5 claims
C24management claimhigh confidence
On 20 October 2026 Intuitive narrowed its full-year 2026 da Vinci procedure growth outlook to 14% to 15%, closer to the midpoint, from 13.5% to 15.5%, after da Vinci procedures grew 14% and total procedures 15% in Q3 2026.
sourceQ2 2026 earnings call transcriptprimaryQ3 2026 earnings call transcriptprimaryForm 8-K and Exhibit 99.1 earnings release for the quarter…primary
against this
- The midpoint of 14.5% is unchanged; narrowing removes the tails and still considers ACA premium subsidy changes and China tender volumes and competitive intensity, among other factors.
- Worldwide growth of 14% is carried by outside-US growth of 20%; United States growth was 10%.
- 2026-10-21editedQ3 2026 results and call: outlook narrowed to 14% to 15% after da Vinci procedure growth of 14% in the quarter.
C26management claimhigh confidence
On its Q3 2026 call on 20 October 2026 Intuitive quantified the instrument pricing actions, the extended use programme and a policy-driven price cut in China from November 2026, at approximately 3% to 5% of da Vinci instrument and accessory revenue for each procedure on a mix-constant basis once fully implemented, against 7% for the 2020 programme; the offsets from force feedback, single-port and da Vinci 5 instruments are not in that figure.
against this
- The 3% to 5% bundles the extended use programme with China's policy cut, so the programme's own share is not stated, and it is struck holding mix constant while management says the offsets are positive and unquantified.
- The United States rollout needs a 510(k) clearance still in process; management expects to start later in the first quarter of 2027 and Europe in the second half of 2027, and said it does not expect the full impact before the end of 2027, which is the 'mostly inside 2027' branch of the pre-registered test.
- 2026-10-21editedQ3 2026 call: management quantified the pricing actions at about 3% to 5% of revenue for each procedure, including China, with the full effect by the end of 2027.
C34management claimhigh confidence
US da Vinci procedure growth was 10% in Q3 2026, against 12% in Q2 2026 and 14% in Q1 2026; management said 10% matched its July expectation and reflects 16% growth in the prior-year quarter, the hardest comparison of the year, and that it is monitoring lower ACA enrollment, Medicaid eligibility changes and potential changes to 340B. US bariatric cases declined at a high single-digit rate in Q2 2026 on rising use of obesity drugs.
against this
- Wells Fargo's analyst called 10% the lowest growth since the pandemic, although stable over two years combined; management gave no recovery figure.
- Management attributed the slowdown to the comparison and to coverage changes, two explanations with different implications, neither quantified. Medtronic's FY2026 10-K independently reports bariatric declines.
- US net da Vinci placements rose 41% and US system placements 27% to 335, which management cited as capacity for later procedure growth.
- 2026-10-21editedQ3 2026 call: US da Vinci procedure growth was 10%, below the 11% line of the pre-registered test.
C08facthigh confidence
On 30 July 2024 the court vacated those market-definition findings on Intuitive's motion for reconsideration, and on 31 March 2025 it certified the plaintiff class and set trial for 14 September 2027. In October 2026, after mediation, Intuitive agreed in writing to settle the class action, without admitting liability, for a one-time $450M payment and mutually agreed injunctive relief, a charge it booked in the third quarter; the settlement still needs preliminary and final court approval and the injunctive terms were not stated in the release. On the call management said the agreement is with US customers in the class action and covers third-party instrument remanufacturers and third-party service providers, sets a framework for how the two work together, and that it does not expect the court's decision until 2027.
sourceForm 10-Q for the quarter ended June 30, 2026primaryForm 8-K and Exhibit 99.1 earnings release for the quarter…primaryQ3 2026 earnings call transcriptprimary
- 2026-10-20editedQ3 2026 results release: the hospital class action was settled for $450M plus injunctive relief, subject to court approval, so the September 2027 trial date no longer stands as the live path.
- 2026-10-21editedQ3 2026 call: scope of the settlement described by management; the injunctive terms are still not published.
C28estimatehigh confidence
A 5-percentage-point cut to trailing instrument and accessory revenue of $6.60B is $330M, which is 9.6% of trailing operating profit of $3.45B and would take the operating margin from 31.3% to 29.2%; at the 3-point low end of management's October range it is $198M, 5.7% of operating profit, taking the margin to 30.0%.
derivedTrailing instrument revenue built from the 10-K's FY2025 figure less H1 2025 plus H1 2026 from the 10-Q; trailing operating profit and revenue from the four filed quarters to 30 June 2026. Assumes the revenue lost carries no cost, which is the right assumption for a price cut on an existing consumable.
against this
- It assumes no volume response. The whole stated purpose of the programme is that lower cost for each use raises adoption in benign and cost-constrained settings, so some of the lost revenue for each procedure comes back as more procedures.
- It assumes the 5-point figure, which is an analyst's estimate the company declined to confirm. The 2020 precedent was characterised as 7 points.
- 2026-10-21editedQ3 2026 call: management's range is 3% to 5%, so the same arithmetic is shown at both ends.
What management did with the money
It bought back $1.44B of stock in the first half, against $181.0M a year earlier, and paid $533.1M to take over its distributors in Italy, Spain and Portugal. It holds $8.63B of cash and investments and borrows nothing.
Insiders in 2026Q2: 20 purchases and 27 sales, from their Form 4 filings.
The evidence under this - 3 claims
C47facthigh confidence
Intuitive repurchased $1,443.5M of stock in the six months to 30 June 2026 against $181.0M a year earlier; shares outstanding fell from 355.1 million to 353.9 million and diluted shares from 364.1 million to 357.3 million year on year.
C49facthigh confidence
Intuitive paid approximately $533.1M in cash in 2026 to acquire the da Vinci distribution businesses of ab medica and affiliates, taking over direct distribution in Italy, Spain, Portugal and associated territories; goodwill rose from $370.3M to $580.6M.
C46facthigh confidence
At 30 June 2026 Intuitive held $8.63B of cash and investments, had total liabilities of $2.58B, and carried no borrowings of any kind.
The price, and where we disagree
In short. Full. The price pays for years of fast growth in operations with steady revenue from each one. Intuitive has now said revenue for each operation will slip by 3% to 5%, and American growth slowed to 10%.
Share price
$393.33
close,
Price for each $1 of yearly profit
44.4
its 6-year normal 73.2
Company value for each $1 of cash profit
30.2
its 6-year normal 53.7
The price cut is now sized: about 3% to 5% of revenue for each operation, rolling out from the first half of 2027 and complete by the end of 2027. That is less than the 7% of the 2020 programme.
The arithmetic is not frightening: 3.1% to 5.3% more operations would offset it, and operations grew 14% in the September quarter. What is not settled is American growth, 10% in the quarter, and what January's outlook says for 2027.
The evidence under this - 3 claims
C26management claimhigh confidence
On its Q3 2026 call on 20 October 2026 Intuitive quantified the instrument pricing actions, the extended use programme and a policy-driven price cut in China from November 2026, at approximately 3% to 5% of da Vinci instrument and accessory revenue for each procedure on a mix-constant basis once fully implemented, against 7% for the 2020 programme; the offsets from force feedback, single-port and da Vinci 5 instruments are not in that figure.
against this
- The 3% to 5% bundles the extended use programme with China's policy cut, so the programme's own share is not stated, and it is struck holding mix constant while management says the offsets are positive and unquantified.
- The United States rollout needs a 510(k) clearance still in process; management expects to start later in the first quarter of 2027 and Europe in the second half of 2027, and said it does not expect the full impact before the end of 2027, which is the 'mostly inside 2027' branch of the pre-registered test.
- 2026-10-21editedQ3 2026 call: management quantified the pricing actions at about 3% to 5% of revenue for each procedure, including China, with the full effect by the end of 2027.
C29estimatehigh confidence
Procedure growth of 5.3% offsets a 5-percentage-point cut to instrument revenue for each procedure and 3.1% offsets a 3-point cut; da Vinci procedures grew 14% in Q3 2026 and 15% in Q2 2026.
derivedOne divided by 0.95 less one, against the Q2 2026 da Vinci procedure growth management reported on the call.
against this
- It holds only while procedure growth holds. US da Vinci procedure growth was 12% in Q2 2026 against 14% in Q1 2026, and management called it the slowest in some time.
- If the programme lands nearer the 2020 precedent's 7 points, the offset needed rises to 7.5% a year, and it must hold in every year the reduction phases in rather than once.
- 2026-10-21editedQ3 2026 call: the quantified range is 3% to 5%, so the offset is shown at both ends, against 14% growth in the quarter.
C34management claimhigh confidence
US da Vinci procedure growth was 10% in Q3 2026, against 12% in Q2 2026 and 14% in Q1 2026; management said 10% matched its July expectation and reflects 16% growth in the prior-year quarter, the hardest comparison of the year, and that it is monitoring lower ACA enrollment, Medicaid eligibility changes and potential changes to 340B. US bariatric cases declined at a high single-digit rate in Q2 2026 on rising use of obesity drugs.
against this
- Wells Fargo's analyst called 10% the lowest growth since the pandemic, although stable over two years combined; management gave no recovery figure.
- Management attributed the slowdown to the comparison and to coverage changes, two explanations with different implications, neither quantified. Medtronic's FY2026 10-K independently reports bariatric declines.
- US net da Vinci placements rose 41% and US system placements 27% to 335, which management cited as capacity for later procedure growth.
- 2026-10-21editedQ3 2026 call: US da Vinci procedure growth was 10%, below the 11% line of the pre-registered test.
How we read the multiple
Buyers pay about 44 times a year's profit, well under Intuitive's six-year normal of about 73, for a business earning more on its money than before.
Counting debt, buyers pay about $39.50 per dollar of yearly operating profit, or about $43,195 for each operation done with its robots in 2025. That needs:
- Operations growing 13% to 15% a year, for years.
- Revenue from each operation holding near today's level.
- The company says the second will slip by 3% to 5% by the end of 2027.
Against its own history. Far cheaper than its own normal on every measure while earning more on its capital: buyers pay less per dollar of profit for a better business.
The evidence under this - 5 claims
C42estimatehigh confidence
At an enterprise value of $136.19B against trailing operating profit of $3.45B, buyers pay $39.50 for each dollar of yearly operating profit - $43,195 of company value for each of the 3,153,000 da Vinci procedures performed in 2025, about 24 times the $1,830 of instrument revenue one procedure yields in a year.
derivedEnterprise value and market value from the pack; trailing operating profit from the four filed quarters to 30 June 2026; procedure count from the 2025 10-K; revenue for each procedure from the Q2 2026 call.
against this
- The denominator is one year's procedures on an installed base that grew 12%, so dividing by a growing number flatters nothing but also understates the multiple against the base that will exist in three years.
- Instrument revenue is not the only revenue each procedure generates - service and lease revenue also scale with the installed base - so 24 times understates what a procedure is worth to the company and overstates how demanding the price is on that one measure.
- Trailing operating profit is struck after a $36M one-off tariff refund and after research and development that management is deliberately growing faster than revenue.
C24management claimhigh confidence
On 20 October 2026 Intuitive narrowed its full-year 2026 da Vinci procedure growth outlook to 14% to 15%, closer to the midpoint, from 13.5% to 15.5%, after da Vinci procedures grew 14% and total procedures 15% in Q3 2026.
sourceQ2 2026 earnings call transcriptprimaryQ3 2026 earnings call transcriptprimaryForm 8-K and Exhibit 99.1 earnings release for the quarter…primary
against this
- The midpoint of 14.5% is unchanged; narrowing removes the tails and still considers ACA premium subsidy changes and China tender volumes and competitive intensity, among other factors.
- Worldwide growth of 14% is carried by outside-US growth of 20%; United States growth was 10%.
- 2026-10-21editedQ3 2026 results and call: outlook narrowed to 14% to 15% after da Vinci procedure growth of 14% in the quarter.
C25management claimhigh confidence
From the first half of 2027 Intuitive plans to increase the number of uses on a subset of EndoWrist instruments, lowering customer cost for each use, targeted at high-volume benign procedures; force feedback, stapling and energy products are excluded.
against this
- Management frames this as an investment in adoption - lower cost supports broader use, which drives utilisation and scale. That framing is unfalsifiable in advance and is the seller describing its own price cut.
- The exclusions are the growing, higher-priced lines: force feedback, stapling and energy. Excluding exactly the instruments whose revenue for each procedure is rising is consistent with defending a headline figure as well as with a targeted cost initiative.
- The 10-K discloses in the same period that the FDA has cleared third parties to remanufacture instruments for the Si, X and Xi generations - the same generations whose instrument lives are now being extended.
C43facthigh confidence
The shares trade at 44.4 times trailing earnings against a six-year median of 73.2, at 12.6 times trailing revenue against a median of 21.0, and at 30.2 times trailing cash profit against a median of 53.7.
C44facthigh confidence
Return on invested capital was 15.1% on a trailing basis against a six-year median of 11.9%, and return on equity 17.8% against 13.8%.
Priced against its rivals
Only SS Innovations International sells the same thing to the same buyers as a large part of what it does. Medtronic does too, but as a small part of a much bigger company, so its price says little about this one. A price comparison needs at least two, so the price is judged against its own history instead.
Private or foreign rivals that cannot be priced: CMR Surgical Ltd., Distalmotion SA, Karl Storz SE & Co. KG, Noah Medical Corporation, Medicaroid Corporation, meerecompany Inc., Beijing Surgerii Robotics Company Limited, Harbin Sizhe Rui Intelligent Medical Equipment Co., Ltd., Shandong Weigao Group Medical Polymer Company Ltd., Shanghai Microport Medbot (Group) Co., Ltd., Shenzhen Edge Medical Co., Ltd.
Where we disagree with the market
The market believes
Americans losing health insurance will slow the operations Intuitive is paid for.
We believe
Insurance is the smaller question. Intuitive is cutting its own instrument prices by 3% to 5%, and American operation growth has slowed to 10%.
The reason for the cut sits in a court docket and a regulator's clearances, not in the growth story management tells: a monopoly finding since withdrawn, a hospital class action heading to trial and a rival cleared to rebuild its instruments.
We would be wrong if American operation growth recovers above 12% in the next quarters while the cut stays at 5% or less.
What analysts say, and the evidence
Analysts positive
73%
of 33, 1 Sep
Four months earlier
66%
of 35, 1 May
The evidence under this - 6 claims
C07facthigh confidence
On 31 March 2024 a federal court ruled that the da Vinci robot and EndoWrist instruments occupy separate product markets for antitrust purposes, that an aftermarket exists for their repair and replacement, and that Intuitive holds monopoly power in it.
C08facthigh confidence
On 30 July 2024 the court vacated those market-definition findings on Intuitive's motion for reconsideration, and on 31 March 2025 it certified the plaintiff class and set trial for 14 September 2027. In October 2026, after mediation, Intuitive agreed in writing to settle the class action, without admitting liability, for a one-time $450M payment and mutually agreed injunctive relief, a charge it booked in the third quarter; the settlement still needs preliminary and final court approval and the injunctive terms were not stated in the release. On the call management said the agreement is with US customers in the class action and covers third-party instrument remanufacturers and third-party service providers, sets a framework for how the two work together, and that it does not expect the court's decision until 2027.
sourceForm 10-Q for the quarter ended June 30, 2026primaryForm 8-K and Exhibit 99.1 earnings release for the quarter…primaryQ3 2026 earnings call transcriptprimary
- 2026-10-20editedQ3 2026 results release: the hospital class action was settled for $450M plus injunctive relief, subject to court approval, so the September 2027 trial date no longer stands as the live path.
- 2026-10-21editedQ3 2026 call: scope of the settlement described by management; the injunctive terms are still not published.
C15facthigh confidence
Intuitive's 10-K states that the FDA has granted 510(k) clearance for the remanufacturing of certain of its instruments for use with da Vinci Si, X and Xi systems, and that such offerings have not had a material impact on its revenues to date.
C16factmedium confidence
Restore Robotics announced two further FDA clearances to remanufacture da Vinci Xi instruments on 31 March 2026, and states that Intuitive has granted approval under its contracts for it to remanufacture any EndoWrist covered by an FDA clearance.
against this
- The second half is the remanufacturer's characterisation of its own contract with Intuitive, not a filed document. Intuitive's 10-K says it generally does not approve customer use of unauthorised instruments, which is not the same statement and may not be inconsistent with it - an approved remanufacturer is by definition authorised.
- Restore Robotics is simultaneously suing Intuitive for antitrust; its complaint was dismissed in November 2025 and is on appeal. A litigant describing its own access is an interested witness.
C26management claimhigh confidence
On its Q3 2026 call on 20 October 2026 Intuitive quantified the instrument pricing actions, the extended use programme and a policy-driven price cut in China from November 2026, at approximately 3% to 5% of da Vinci instrument and accessory revenue for each procedure on a mix-constant basis once fully implemented, against 7% for the 2020 programme; the offsets from force feedback, single-port and da Vinci 5 instruments are not in that figure.
against this
- The 3% to 5% bundles the extended use programme with China's policy cut, so the programme's own share is not stated, and it is struck holding mix constant while management says the offsets are positive and unquantified.
- The United States rollout needs a 510(k) clearance still in process; management expects to start later in the first quarter of 2027 and Europe in the second half of 2027, and said it does not expect the full impact before the end of 2027, which is the 'mostly inside 2027' branch of the pre-registered test.
- 2026-10-21editedQ3 2026 call: management quantified the pricing actions at about 3% to 5% of revenue for each procedure, including China, with the full effect by the end of 2027.
C34management claimhigh confidence
US da Vinci procedure growth was 10% in Q3 2026, against 12% in Q2 2026 and 14% in Q1 2026; management said 10% matched its July expectation and reflects 16% growth in the prior-year quarter, the hardest comparison of the year, and that it is monitoring lower ACA enrollment, Medicaid eligibility changes and potential changes to 340B. US bariatric cases declined at a high single-digit rate in Q2 2026 on rising use of obesity drugs.
against this
- Wells Fargo's analyst called 10% the lowest growth since the pandemic, although stable over two years combined; management gave no recovery figure.
- Management attributed the slowdown to the comparison and to coverage changes, two explanations with different implications, neither quantified. Medtronic's FY2026 10-K independently reports bariatric declines.
- US net da Vinci placements rose 41% and US system placements 27% to 335, which management cited as capacity for later procedure growth.
- 2026-10-21editedQ3 2026 call: US da Vinci procedure growth was 10%, below the 11% line of the pre-registered test.
What could go wrong, and how we would know
The risks
- A deeper cut. A 5-point cut is about $330M a year; management's low end is about $198M. A cut above 5, landing mostly in 2027, bites harder.
- Slower American growth. American operation growth slowed to 10%, and more than half of da Vinci operations treat benign conditions that patients can put off.
- Rebuilt instruments. Others are cleared to remanufacture Intuitive's instruments, the most profitable line, without touching the robot.
- Rival robots. Medtronic names Hugo among its surgical division's growth drivers, and filed it for general surgery in June 2026.
- The court. Intuitive agreed to settle the hospital class action for $450M plus terms on outside rebuilders and servicers, pending court approval. The terms are unpublished.
The evidence under this - 8 claims
C28estimatehigh confidence
A 5-percentage-point cut to trailing instrument and accessory revenue of $6.60B is $330M, which is 9.6% of trailing operating profit of $3.45B and would take the operating margin from 31.3% to 29.2%; at the 3-point low end of management's October range it is $198M, 5.7% of operating profit, taking the margin to 30.0%.
derivedTrailing instrument revenue built from the 10-K's FY2025 figure less H1 2025 plus H1 2026 from the 10-Q; trailing operating profit and revenue from the four filed quarters to 30 June 2026. Assumes the revenue lost carries no cost, which is the right assumption for a price cut on an existing consumable.
against this
- It assumes no volume response. The whole stated purpose of the programme is that lower cost for each use raises adoption in benign and cost-constrained settings, so some of the lost revenue for each procedure comes back as more procedures.
- It assumes the 5-point figure, which is an analyst's estimate the company declined to confirm. The 2020 precedent was characterised as 7 points.
- 2026-10-21editedQ3 2026 call: management's range is 3% to 5%, so the same arithmetic is shown at both ends.
C34management claimhigh confidence
US da Vinci procedure growth was 10% in Q3 2026, against 12% in Q2 2026 and 14% in Q1 2026; management said 10% matched its July expectation and reflects 16% growth in the prior-year quarter, the hardest comparison of the year, and that it is monitoring lower ACA enrollment, Medicaid eligibility changes and potential changes to 340B. US bariatric cases declined at a high single-digit rate in Q2 2026 on rising use of obesity drugs.
against this
- Wells Fargo's analyst called 10% the lowest growth since the pandemic, although stable over two years combined; management gave no recovery figure.
- Management attributed the slowdown to the comparison and to coverage changes, two explanations with different implications, neither quantified. Medtronic's FY2026 10-K independently reports bariatric declines.
- US net da Vinci placements rose 41% and US system placements 27% to 335, which management cited as capacity for later procedure growth.
- 2026-10-21editedQ3 2026 call: US da Vinci procedure growth was 10%, below the 11% line of the pre-registered test.
C06facthigh confidence
More than half of da Vinci procedures performed are for benign conditions, and those procedures are the more deferrable ones.
C15facthigh confidence
Intuitive's 10-K states that the FDA has granted 510(k) clearance for the remanufacturing of certain of its instruments for use with da Vinci Si, X and Xi systems, and that such offerings have not had a material impact on its revenues to date.
C16factmedium confidence
Restore Robotics announced two further FDA clearances to remanufacture da Vinci Xi instruments on 31 March 2026, and states that Intuitive has granted approval under its contracts for it to remanufacture any EndoWrist covered by an FDA clearance.
against this
- The second half is the remanufacturer's characterisation of its own contract with Intuitive, not a filed document. Intuitive's 10-K says it generally does not approve customer use of unauthorised instruments, which is not the same statement and may not be inconsistent with it - an approved remanufacturer is by definition authorised.
- Restore Robotics is simultaneously suing Intuitive for antitrust; its complaint was dismissed in November 2025 and is on appeal. A litigant describing its own access is an interested witness.
C12facthigh confidence
Medtronic received FDA clearance for the Hugo robotic-assisted surgery system in urologic procedures in December 2025, and on 3 June 2026 submitted 510(k) filings for general surgery including hernia repair and for gynecologic surgery.
C13facthigh confidence
Medtronic's Form 10-Q for the quarter ended 31 July 2026 names the Hugo system among the drivers of growth in its Surgical & Endoscopy division.
C08facthigh confidence
On 30 July 2024 the court vacated those market-definition findings on Intuitive's motion for reconsideration, and on 31 March 2025 it certified the plaintiff class and set trial for 14 September 2027. In October 2026, after mediation, Intuitive agreed in writing to settle the class action, without admitting liability, for a one-time $450M payment and mutually agreed injunctive relief, a charge it booked in the third quarter; the settlement still needs preliminary and final court approval and the injunctive terms were not stated in the release. On the call management said the agreement is with US customers in the class action and covers third-party instrument remanufacturers and third-party service providers, sets a framework for how the two work together, and that it does not expect the court's decision until 2027.
sourceForm 10-Q for the quarter ended June 30, 2026primaryForm 8-K and Exhibit 99.1 earnings release for the quarter…primaryQ3 2026 earnings call transcriptprimary
- 2026-10-20editedQ3 2026 results release: the hospital class action was settled for $450M plus injunctive relief, subject to court approval, so the September 2027 trial date no longer stands as the live path.
- 2026-10-21editedQ3 2026 call: scope of the settlement described by management; the injunctive terms are still not published.
What we still do not know
- How much of the 3% to 5% is the longer-life instruments and how much is China's price cut. Intuitive gave one combined figure.
- How many complications the robot actually prevents. Nobody outside the company has measured it.
- What share of surgery is robotic today. The last outside measure is from 2018.
The evidence under this - 3 claims
C26management claimhigh confidence
On its Q3 2026 call on 20 October 2026 Intuitive quantified the instrument pricing actions, the extended use programme and a policy-driven price cut in China from November 2026, at approximately 3% to 5% of da Vinci instrument and accessory revenue for each procedure on a mix-constant basis once fully implemented, against 7% for the 2020 programme; the offsets from force feedback, single-port and da Vinci 5 instruments are not in that figure.
against this
- The 3% to 5% bundles the extended use programme with China's policy cut, so the programme's own share is not stated, and it is struck holding mix constant while management says the offsets are positive and unquantified.
- The United States rollout needs a 510(k) clearance still in process; management expects to start later in the first quarter of 2027 and Europe in the second half of 2027, and said it does not expect the full impact before the end of 2027, which is the 'mostly inside 2027' branch of the pre-registered test.
- 2026-10-21editedQ3 2026 call: management quantified the pricing actions at about 3% to 5% of revenue for each procedure, including China, with the full effect by the end of 2027.
C09facthigh confidence
The costliest inpatient harms, including surgical site infections, add approximately $30,000 to the cost of the hospital stay.
C20facthigh confidence
Robotic surgery rose from 1.8% of general surgery procedures in 2012 to 15.1% in 2018 across 73 Michigan hospitals, a slope of 2.1 percentage points a year, while open surgery fell from 42.4% to 32.4%.
What would change our view
- Neutral→AttractiveThe price cut is named and the volume more than covers it
It needs all of:
- ○Intuitive names the price cut, and instrument revenue for each operation falls less than 10% during 2027.checked at the next results, due by 28 Jan
- ○da Vinci operations keep growing at 13% a year or more, so volume carries the cut.checked at the next results, due by 28 Jan
- Neutral→AttractiveThe price no longer needs both halves
It needs all of:
- ○The company's value falls to about 30 times yearly operating profit, from 39.5, through profit growing or the price falling.about ≈$298.73 today, 24% below the last close
- ○The hospital class action ends without a ruling that restricts how replacement instruments are supplied.watched as it happens
We would also be wrong if
- A rival robot wins more than a tenth of American robot sales in a year.
- American instrument sales stop growing while the number of installed robots still rises.
- da Vinci operation growth settles below 10% a year for two quarters running.
What is coming
- 28 January 2027 Q4 2026 results and 2027 guidance: The first full-year guide that carries the pricing actions, the 2027 procedure growth range the PSUs now pay on, and whether United States da Vinci procedure growth recovers from 10%.
Every dated event ahead
- 28 January 2027 Q4 2026 results and 2027 guidance: The first full-year guide that carries the pricing actions, the 2027 procedure growth range the PSUs now pay on, and whether United States da Vinci procedure growth recovers from 10%.
- June 2027 Extended use instruments launch: Whether instrument revenue per procedure falls by about what the company quantified, and whether hospitals respond with more benign cases.
- 31 December 2027 Court approval of the class action settlement: Whether the court approves the $450M settlement, and the published injunctive terms on how Intuitive supplies replacement instruments.
Since we wrote this
Written
19 Sep
Price the thesis read
$393.33
18 Sep
- 21 OctEarningsCall sized the price cut at 3% to 5%; US growth 10%The cut is smaller than the 5 points we assumed, but US procedure growth slowed below our 11% line. The test read against us and the view held.
- 20 OctEarningsQ3 beat; hospital class action settled for $450MProcedures grew about 14%. The settlement ends the 2027 trial risk, but its terms are unknown and the price-cut size is still unread.
- 5 OctThesis reviewThe long case now sits under the verdictAfter the five-name pilot, the owner asked for the long case on every thesis.
- 4 OctThesis reviewOwner's checklist: revenue streams, cost of growth, management, catalystsThe owner's checklist found the method silent on who runs the company, what growth costs, where the money comes from and what is dated ahead; this pass fills those four blocks from the proxy and filings.
- 19 SepThesis writtenNeutral, medium convictionWritten two months after the shares fell 14.1% on results that beat, and a month before Intuitive says how deep its instrument price cut will be.
Also checked 3 times with nothing new to act on.
Sources 22
Where this came from
Sources - 22
Every claim above cites one of these, or states the reasoning that derived it. The quote is frozen at the date it was read: a link can rot, and an agent fetch returns a reading of a page rather than the page. Backs counts the whole claim ledger, so it can name a claim this page does not surface.
- S01primarycompany filing2026-02-03the business description, the Competition section naming fourteen companies, the remanufactured-instrument risk factor and the FDA clearance behind it, the GLP-1 risk factor, China provincial price limits, the 2025 tariff cost, and the full-year procedure, instrument, system and installed-base figuresbacksC01C03C04C06C11C15C18C33C35C36C38C45C53C63C66C67C71
- S02primarycompany filing2026-07-21the income statement, the revenue split by instruments, systems and service, the balance sheet, the cash flow statement, share-based compensation, the one-segment disclosure, and Note 8's recital of every antitrust proceeding including the class certification and the September 2027 trial datebacksC02C07C08C10C22C30C31C38C40C43C46C47C48C49C50C52C60C67
- S03primarytranscript2026-07-16the extended use programme's design and management's refusal to quantify it; revenue for each procedure; the US procedure deceleration and the bariatric decline; China placements; the tariff refund; guidance. Also the analyst questions, which are a separate origin from the answers - the 5-point estimate of the programme's effect came from Bank of America's analyst, not from the company
Beginning in the first half of 27, we plan to introduce an updated subset of ENDORIST instruments for use with our fourth and fifth generation da Vinci platforms that feature increased useful lives and lower customer cost per use.
backsC03C05C10C23C24C25C26C27C32C34C37C48C56C57C58C59C60 - S04primarycompany filing2026-07-16the procedure and placement counts published alongside the callbacksC23C57
- S05primaryvendor data2026-09-19Research pack, frozen beside this thesiscontent/ISRG/research-pack.jsonprice, the 252-day and 126-day price-move decomposition, trailing multiples against their six-year medians, return on invested capital, the analyst rating series, FINRA short interest, the earnings-surprise history, headcount and revenue for each employee, and the filed-competitor cohort's unavailabilitybacksC30C38C39C40C41C43C44C45C53C54
- S06primarycompany filing2026-06-18a competitor's own confirmation that surgery is shifting to robots and that bariatric volumes are falling; the Hugo product description; and the segment table showing Surgical & Endoscopy net sales of $6,764M against total net sales of $36,364M
The growth in Surgical was partially offset by Advanced Stapling due to shifts to robotic surgery and bariatric procedure declines.
backsC17C45 - S07primarycompany filing2026-09-03Medtronic naming Hugo among the drivers of its own divisional growth, which is the attacker reporting traction rather than the incumbent assessing it
The net sales increase was primarily due to growth in Surgical, with strength in LigaSure vessel sealing technology, V-Loc barbed sutures, ProGrip self-gripping polyester mesh, Hugo robotic assisted surgery (RAS) system, and Endoscopy.
backsC13 - S08primaryindustry data2020-01-10Sheetz KH, Claflin J, Dimick JB. Trends in the Adoption of Robotic Surgery for Common Surgical Procedures. JAMA Network Open, 2020 JAMA Network Openthe rate at which surgery is moving to robots, measured by academics across 73 hospitals rather than asserted by a vendor - the number machine.current needs, and the penetration factor in machine.prize
The use of robotic surgery increased from 1.8% in 2012 to 15.1% in 2018 ... slope, 2.1% per year; 95% CI, 1.9%-2.3% ... the proportional use of open surgery was 42.4% in 2012 compared with 32.4% in 2018
backsC20 - S09primarygovernment data2017-12-01Overview of Operating Room Procedures During Inpatient Stays in U.S. Hospitals, 2014. HCUP Statistical Brief #233, Agency for Healthcare Research and Quality Agency for Healthcare Research and Qualitythe base of machine.prize, counted in operations by the federal agency that counts them
In 2014, 10.1 million inpatient hospital stays involved operating room (OR) procedures with a total of 14.2 million OR procedures.
backsC19 - S10primaryindustry data2019-01-01Estimating the hospital costs of inpatient harms. Journal of Hospital Medicine Journal of Hospital Medicinewhat a surgical complication costs the hospital, from HCUP state inpatient data rather than from a device maker - the quantity machine.moat.buyer_economics needs
The costliest inpatient harms, such as surgical site infections and severe pressure ulcers, are associated with approximately $30 000 in additional index stay costs per harm.
backsC09 - S11primarycompany release2026-03-31Restore Robotics Receives FDA 510(k) Clearance for Two Additional da Vinci Xi Robotic Instruments Restore Roboticsthe remanufacturer's own account of its clearances, and its statement that Intuitive has granted approval under its contracts to remanufacture any cleared EndoWrist - a claim about the instrument lock made by the party attacking it
Restore Robotics today announced it has received additional 510(k) clearances from the U.S. Food and Drug Administration (FDA) for the remanufacturing of two more da Vinci Xi robotic surgical instruments.
backsC16 - S12primarycompany release2026-06-03the date and scope of Medtronic's US expansion filings, and its statement that Hugo received FDA clearance for urologic surgical procedures in December 2025
General surgery indication including hernia repair - 510(k) clearance submitted
backsC12 - S13primarycompany release2026-01-07Johnson & Johnson Submits OTTAVA Robotic Surgical System to the U.S. Food and Drug Administration Johnson & Johnsonthe date and pathway of the second large rival's US submission, from the rival itself
Johnson & Johnson today announced that the company has submitted the OTTAVA Robotic Surgical System to the U.S. Food and Drug Administration (FDA)
backsC14 - S14primarycompany filing2026-02-11Johnson & Johnson Form 10-K for the fiscal year ended December 28, 2025 Johnson & Johnsona negative finding: the document was fetched and read and contains neither OTTAVA nor the phrase surgical robotic, five weeks after the FDA submission was announced. This is why Johnson & Johnson fails the cohort's confirmation gatebacksC45
- S15primarycompany filing2026-03-10SS Innovations International, Inc. Form 10-K for the fiscal year ended December 31, 2025 SS Innovations International, Inc.the one named competitor whose own annual report describes the same product sold to the same buyer across the whole companybacksC45
- S16tertiarynews2026-07-17the stated objection on the day the shares repriced, and two named analysts' readings of it - evidence for what the common view is, not evidence about the business
Intuitive Surgical shares fell more than 12% before the bell on Friday after it maintained its global growth forecast
backsC39 - S17primarycompany filing2026-09-19the Rule 10b5-1 checkbox on every open-market sale, which the vendor feed dropsbacksC55
- S18primarycompany filing2026-01-14the metric table the 10-K does not carry: instrument and accessory revenue for each procedure by year and quarter, placements by geography and by model, trade-in counts, lease placements, average selling price, and the installed base with the retirement audit behind itbacksC61C62C63C64C65
- S19primarycompany filing2026-03-13beneficial ownership as of December 31, 2025, the executive officers and their careers, the July 2025 chief executive transition, the 2025 and 2026 bonus and PSU design and the 2025 payoutbacksC68C69C70
- S20primarycompany filing2026-10-04the filer's own tagged figures for 2021 to 2025 and the four quarters to June 2026: revenue, gross and operating profit, R&D, SG&A, stock pay, capital spending, repurchases, stock-plan cash flows and diluted sharesbacksC67C71
- S21primarycompany filing2026-10-20third quarter placements, procedure growth, revenue, non-GAAP and GAAP profit, the $450M antitrust class action settlement, the repurchases and the 2026 outlookbacksC08C24
- S22primarytranscript2026-10-20the quantified size of the instrument pricing actions and China price cut, the timing of the rollout, US da Vinci procedure growth of 10% and why, the narrowed 2026 procedure outlook, the settlement's scope as management described it, and eight analysts' questions
we expect these pricing actions and the China price reduction to lower da Vinci I&A revenue per procedure by approximately 3% to 5% on a mix constant basis once fully implemented
backsC05C08C24C26C34